Top clinical trials for new treatments are currently recruiting for mesothelioma patients. Get access to new mesothelioma health options today.

Current Recruiting Clinical Trials

Since mesothelioma is such a rare cancer, new treatment options have been few and far between. As new treatments are developed, patients are given access to these investigational medications by participating in clinical trials. Learn more about how clinical trials work.

Clinical trials can offer patients treatment options that aren’t available to all patients. There is also potential to be part of a trial that can lead to recovery.

Clinical trials are an essential part of furthering mesothelioma research toward finding new treatments. Use the tool below to find a recruiting mesothelioma clinical trial that fits your needs.

This trial tests a novel group of drugs as a treatment for peritoneal surface malignancies, including peritoneal mesothelioma. Patients in this trial receive a DC vaccine, which is a vaccine created using cells from the patient’s body. Patients also receive a combination of 3 drugs: celecoxib, interferon alfa (IFN), and rintatolimod.

This trial is evaluating the use of intensity modulated radiation therapy (IMRT) in patients undergoing standard chemotherapy and a lung sparing pleurectomy with decortication. IMRT is a relatively new form of radiation that can target specific areas for radiation, avoiding healthy tissue.

An altered version of the measles virus was created to infect and kill cancer cells without damaging healthy cells. Researchers expect the measles to trigger the immune system to attack the tumor cells.

Mithramycin, also known as plicamycin, is an anti-cancer drug. Researchers believe it may be effective in treating certain cancers of the chest, including pleural mesothelioma. This trial is for patients whose mesothelioma cannot be surgically removed.

LY3023414 is a drug being tested to treat patients with advanced stages of mesothelioma and other cancers. It is a capsule patients can take orally. LY3023414 works by blocking two of the proteins that help cancer grow. This trial is for patients whose tumors are not responding to standard treatments.

This trial treats pleural mesothelioma with the virotherapy drug GL-ONC1. GL-ONC1 is a modified form of the vaccinia virus, which was used to make the smallpox vaccine. This treatment has already proven to be effective in some cases of mesothelioma. Researchers believe it may be effective for all stages of mesothelioma.

Nintedanib may be able to treat advanced pleural mesothelioma by inhibiting an enzyme called kinase. In this trial, patients will receive nintedanib or a placebo treatment. All patients will also receive pemetrexed and cisplatin which are the standard chemotherapy for mesothelioma.

Neoadjuvant treatments are used before surgery to shrink tumors and improve surgery results. Patients in this trial will be treated with defactinib (VS-6063) twice daily before having surgery to remove their tumors. Defactinib targets mesothelioma stem cells by blocking certain signaling pathways.

CB-839 fights mesothelioma by blocking the enzyme glutaminase. Glutaminase is part of the amino acid glutamine, which helps tumor cells produce energy to grow and survive. Patients in this trial take the CB-839 capsule orally 2-3 times a day. This trial is for patients with solid tumors, including mesothelioma.

Participants in this trial will undergo surgery and then a portion of patients will receive photodynamic therapy (PDT). Patients undergoing PDT will receive Photofrin. Photofrin is a drug that can make mesothelioma cells sensitive to light so that doctors are able to destroy them with a laser light.

This trial is for patients with unresectable pleural mesothelioma. Patients will take alisertib tablets twice a day for the first 7 days of a 21 day cycle. Doctors will check the patient’s disease status after every 2 cycles. Patients may continue taking alisertib as long as it benefits them.

The standard treatment for pleural mesothelioma is chemotherapy with two drugs: pemetrexed (Alimta) and cisplatin. This trial tests adding amatuximab to the combination. Patients with unresectable pleural mesothelioma are eligible if they have not had systemic chemotherapy or radiation therapy.

Mesothelioma patients may be eligible to participate in this trial if their disease has progressed despite systemic chemotherapy treatments. Patients in this trial are treated with 2 drugs, enoblituzumab (MGA271) and Yervoy (ipilimumab). Both drugs work with the body’s immune system to fight cancer.

Immunotherapies work with the immune system to fight cancer. In this trial, researchers are using the antibody drug pembrolizumab (Keytruda) to block the mesothelioma cancer cells from receiving certain proteins that suppress the immune system.

T cells are an important part of the immune system. In this trial, researchers take T cells from each patient and modify them to target WT1, a protein found on the surface of mesothelioma cells. The modified T cells are returned to the patient’s body, along with two immune boosting drugs, to fight mesothelioma.

Most mesothelioma cells over express a protein called mesothelin. Researchers take immune cells, called T cells, from each patient in this trial and modify them to target mesothelin. The modified T cells are returned to each patient to help the immune system fight mesothelioma. Some patients also receive chemotherapy.

A pleuroscopy is a minimally invasive procedure during which doctors take fluid and tumor samples. In this trial doctors use a freezing spray, called cryotherapy, during the pleuroscopy. Researchers believe freezing tumors can induce an immune response. Patients will also undergo standard mesothelioma surgery about 14 days after cryotherapy.

Patients in this trial will receive two drugs: MGA271 (enoblituzumab) and Keytruda (pembrolizumab). Both of these drugs work to fight mesothelioma by blocking different proteins that mesothelioma cells need to grow and survive. This trial is for patients whose mesothelioma progressed after chemotherapy treatment.

This trial is for patients whose mesothelioma has spread to other parts of their body. For these patients, standard chemotherapy did not work to treat their mesothelioma. In this trial, participants will receive a drug called methoxyamine which may be able to make standard chemotherapy more effective.

Nintedanib may be able to block certain enzymes that mesothelioma cells need to grow. Nintedanib is being tested to treat patients whose mesothelioma returned after previous treatment. Patients with recurrent or stage IV mesothelioma may be eligible to participate in this trial.

MEDI4736 and tremelimumab are both immunotherapy drugs and treat mesothelioma by encouraging the body’s immune system to attack the cancer. In this trial some patients will receive MEDI4736 and some patients will receive both MEDI4736 and tremelimumab. All participants will be treated with necessary surgery.

Anetumab ravtansine may be able to prevent disease progression in patients whose mesothelioma cells overexpress the protein mesothelin. This trial is for pleural mesothelioma patients who have already been treated with chemotherapy and need a 2nd line treatment.

This trial explores a new way of treating patients with chemotherapy. Using transarterial chemoperfusion, doctors can administer chemotherapy drugs directly to the location of a patient’s cancer. This trial is for pleural mesothelioma patients who are not eligible for surgery.

The purpose of this trial is to assess the safety of MGD009 at different doses. MGD009 inhibits a protein called B7-H3 which is overexpressed in some patients’ mesothelioma cells. This drug also helps the body’s immune system recognize these cells so that it can attack them.

Anetumab ravtansine is a drug that targets cells that overexpress a protein called mesothelin. Most mesothelioma cells overexpress mesothelin. In this trial, researchers treat mesothelioma patients with anetumab ravtansine in combination with standard chemotherapy for mesothelioma.

Accelerated hypofractionated radiation therapy is radiation treatments given in fewer treatments but in larger doses. Researchers believe giving this type of radiation immediately before surgery may be able to reduce side effects and improve survival for pleural mesothelioma patients.

Patients in this trial are treated with the immunotherapy drug pembrolizumab (Keytruda), then surgery, and then chemotherapy. To participate in this trial, patients must have pleural mesothelioma and be able to undergo surgery.

ADI-PEG 20 is an experimental drug that blocks an amino acid called arginine. Researchers believe that restricting arginine will cause pleural mesothelioma cells to starve and die. Patients in this trial will receive ADI-PEG 20 as well as standard chemotherapy with pemetrexed (Alimta) and cisplatin.

LMB-100 is a novel drug that may be able to kill cancer cells by binding to a protein called mesothelin. Mesothelin is not usually found in normal tissue but exists in high levels in most mesothelioma cells. Researchers hope LMB-100 will become an effective treatment option for mesothelioma patients who aren’t eligible for surgery.

Mithramycin is a drug being tested to treat cancers in the chest, including pleural mesothelioma. Every 14 days, patients in this trial will be treated with mithramycin for 24 hr through an IV. This trial is meant to treat patients whose cancer is inoperable.

Patients in this trial will take tazemetostat orally twice a day. Tazemetostat may be able to slow tumor cell proliferation by inhibiting the enzyme EZH2. This trial is for any type of mesothelioma patient whose disease has been difficult to treat or is recurring.

This trial tests Keytruda (pembrolizumab, MK-3475) in combination with CRS-207. Both of these immunotherapy drugs have had amazing results in previous and ongoing clinical trials. This trial is intended for pleural mesothelioma patients who have been failed by past treatments.

Find a Recruiting Trial


Newly Diagnosed?
Surgical Candidate?
Had Standard Chemotherapy?

Top Mesothelioma Trials


ID: {{trial.trialId}}


Sponsor | {{trial.sponsor}}


    Specialized for Patients Who Are:
  • {{ trial.specialized1 }}
  • {{ trial.specialized2 }}
  • {{ trial.specialized3 }}
Load More

Get More Information on Clinical Trials

Connect with Clinical Trials Now

One of the best ways to improve your prognosis and the likelihood of beating mesothelioma is through clinical trials. There are many clinical trials available for both pleural and peritoneal mesothelioma. Our patient advocates can help you find and enroll in a clinical trial that matches your needs.

Clinical Trials Can Provide:

  • Exclusive access to promising new procedures.
  • One-on-one care from leading mesothelioma specialists.
  • Alternative options for patients who have exhausted traditional treatments.